Storia in 2 fonti

Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.

Raccontata da

ynetnews.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.

originale

ynetnews.com1 mese fa

Teva advances experimental vitiligo drug after encouraging early results

Israeli drugmaker says TEV-408, an anti-IL-15 antibody designed for quarterly dosing, improved skin pigmentation in an early-stage study and will move into Phase 2b development later this year

Leggi questa versione → originale

Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)

Confronto fonti

Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)

Teva advances experimental vitiligo drug after encouraging early results

Timeline cronologica

Teva advances experimental vitiligo drug after encouraging early results

Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)

Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study - Forte Bi